IDEXX Laboratories Price Target Raised to $135.00 at Raymond James (IDXX)
Raymond James boosted their target price on shares of IDEXX Laboratories (NASDAQ:IDXX) from $123.00 to $135.00 in a report released on Monday, American Banking and Market News reports. The firm currently has an “outperform” rating on the stock. Raymond James’ price objective indicates a potential upside of 8.79% from the stock’s previous close.
A number of other firms have also recently commented on IDXX. Analysts at Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $120.00 to $135.00 in a research note on Monday, April 14th. They now have a “buy” rating on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of IDEXX Laboratories in a research note on Monday, March 10th. They set a “neutral” rating and a $125.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of IDEXX Laboratories from $99.00 to $116.00 in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $127.75.
Shares of IDEXX Laboratories (NASDAQ:IDXX) traded up 0.27% on Monday, hitting $124.09. The stock had a trading volume of 214,350 shares. IDEXX Laboratories has a 52 week low of $81.57 and a 52 week high of $129.27. The stock’s 50-day moving average is $122.0 and its 200-day moving average is $113.7. The company has a market cap of $6.403 billion and a price-to-earnings ratio of 35.56.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Friday, April 25th. The company reported $0.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.87 by $0.02. The company had revenue of $360.20 million for the quarter, compared to the consensus estimate of $361.58 million. During the same quarter last year, the company posted $0.81 earnings per share. IDEXX Laboratories’s revenue was up 8.5% compared to the same quarter last year. Analysts expect that IDEXX Laboratories will post $3.84 EPS for the current fiscal year.
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.